Gensight Biologics Aktie [WKN DE: A2ANGZ / ISIN: FR0013183985]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Gensight Biologics SA

15.09.20		GenSight Biologics Submits EU Marketing Authorisation Application for LUMEVOQ® Gene Therapy to Treat Vision Loss Due to Leber Hereditary Optic Neuropathy (LHON) (Businesswire)
06.07.20		GenSight Biologics Reports Sustained Efficacy and Safety Among LHON Patients Three Years After LUMEVOQ® Treatment (Businesswire)
03.03.20		GenSight Biologics Announces Presentation of Bilateral Visual Recovery From GS010 (LUMEVOQ™) Phase III Trials at the 46th Annual Meeting of NANOS (Businesswire)
11.12.19		GenSight Biologics reports findings from REALITY study and REVERSE-RESCUE analysis highlighting positive benefits from LUMEVOQ™ (GS010) compared to LHON natural history (Businesswire)
09.12.19		The Quinze-Vingts Hospital and GenSight Biologics Announce a First Temporary Authorization for Use (ATU) for LUMEVOQ™ (GS010) in France (Businesswire)
09.10.19		GenSight Biologics Reports Evidence of GS010 DNA Transfer to Contralateral Eye of Primates Unilaterally Injected With GS010 Gene Therapy (Businesswire)
08.10.19		GenSight Biologics Appoints Magali Taiel as Chief Medical Officer (Businesswire)
23.09.19		GenSight Biologics Reports Sustained Efficacy and Safety at 96 Weeks in RESCUE Phase III Clinical Trial of GS010 for the Treatment of Leber Hereditary Optic Neuropathy (LHON) (Businesswire)
11.07.19		GenSight Biologics completes enrollment of GS010 REFLECT Phase III trial in the treatment of Leber Hereditary Optic Neuropathy ahead of schedule (Businesswire)
29.05.19		Sustained Bilateral Improvement from GenSight Biologics’ REVERSE Phase III Clinical Trial Represents Transformative Therapeutic Benefit for Patients, Key Opinion Leaders Conclude (Businesswire)
15.05.19		GenSight Biologics Reports Positive 96-Week Data from REVERSE Phase III Clinical Trial of GS010 for the Treatment of Leber Hereditary Optic Neuropathy (LHON) (Businesswire)
06.05.19		GenSight Biologics Announces Presentation of 72-Week Data from the REVERSE Phase III Trial of GS010 at the Annual Meeting of the American Academy of Neurology (AAN) (Businesswire)
25.04.19		GenSight Biologics Announces Presentation of 72-Week Data from the REVERSE & RESCUE Phase III Trials of GS010 at the Annual Meeting of ARVO (Businesswire)
17.04.19		GenSight Biologics Reports Positive Follow-up Results at Week 72 of the RESCUE Phase III Clinical Trial of GS010 in Leber Hereditary Optic Neuropathy (LHON) (Businesswire)
15.03.19		GenSight Biologics Announces Presentation of 72-Week Data From the REVERSE Phase III Trial of GS010 at the 45th Annual Meeting of NANOS (Businesswire)
12.02.19		GenSight Biologics Announces Publication of Positive Safety Data from Phase I/II Trial of GS010 in the JAMA Ophthalmology (Businesswire)
12.12.18		GenSight Biologics Reports Sustained Quality of Life Improvements at Week 72 of Phase III REVERSE Clinical Trial of GS010 for the Treatment of Leber Hereditary Optic Neuropathy (LHON) (Businesswire)
26.10.18		GenSight Biologics Enrolls First Subject in First-in-man PIONEER Phase I/II Clinical Trial of GS030 Combining Gene Therapy and Optogenetics for the Treatment of Retinitis Pigmentosa (Businesswire)
18.10.18		GenSight Biologics reports positive 72-week data from REVERSE Phase III clinical trial of GS010 for the treatment of Leber Hereditary Optic Neuropathy (LHON) (Businesswire)
18.10.18		GenSight Biologics reports positive 72-week data from REVERSE Phase III clinical trial of GS010 for the treatment of Leber Hereditary Optic Neuropathy (LHON) (Businesswire)
13.09.18		GenSight Biologics Provides an Update on the Clinical and Regulatory Pathways for GS010 (Businesswire)
20.06.18		GenSight Biologics : Key Opinion Leaders Highlight GS010 Efficacy and Patient Benefits in Discussion of Findings from REVERSE Phase III Clinical Trial (Businesswire)
12.06.18		GenSight Biologics Reports Positive Additional Data from REVERSE Phase III Clinical Trial of GS010 for Treatment of Leber Hereditary Optic Neuropathy (LHON) (Businesswire)
21.05.18		GenSight Biologics to Host KOL Event on June 12, 2018 (Businesswire)
26.04.18		GenSight Biologics to Present Data on GS010 and GS030 at the Annual Meeting of ARVO (Businesswire)
03.04.18		GenSight Biologics announces topline results from REVERSE Phase III clinical trial of GS010 in patients with Leber Hereditary Optic Neuropathy (LHON) (Businesswire)
28.02.18		GenSight Biologics Reports Full Year 2017 Financial Results (Businesswire)
20.02.18		GenSight Biologics Announces Publication of Positive Data from Phase I/II Trial and Long-Term Follow-up of GS010 in Ophthalmology, the Journal of the American Academy of Ophthalmology (Businesswire)
25.01.18		GenSight Biologics Appoints Julio Benedicto as Vice President of Marketing (Businesswire)
25.01.18		GenSight Biologics Reports €55 Million 2017 Year-End Cash Position and Provides Corporate Update (Businesswire)
17.01.18		GenSight Biologics Announces Its 2018 Financial Calendar (Businesswire)
10.01.18		GenSight Biologics Receives MHRA Approval to Initiate Phase I/II PIONEER Clinical Trial of GS030 Gene Therapy in Retinitis Pigmentosa (Businesswire)
06.11.17		GenSight Biologics to Participate in Multiple Conferences in November (Businesswire)
26.10.17		GenSight Biologics Reports its Cash Position as of September 30, 2017 (Businesswire)
25.10.17		GenSight Biologics Appoints Barrett Katz as Chief Medical Officer (Businesswire)
16.10.17		GenSight Biologics to Present Data on GS010 and GS030 at the 2017 Congress of the European Society of Gene & Cell Therapy (Businesswire)
04.10.17		GenSight Biologics to Attend Chardan Gene Therapy Conference (Businesswire)
02.10.17		GenSight Biologics Integrates the Enternext® PEA-PME 150 Index (Businesswire)
19.09.17		GenSight Biologics Integrates the CAC® Small, CAC® Mid and Small and CAC® All-Tradable Euronext Indexes (Businesswire)
01.08.17		GenSight Biologics Completes Enrollment of RESCUE Phase III Study of GS010 in the Treatment of Leber’s Hereditary Optic Neuropathy (Businesswire)
28.07.17		GenSight Biologics Reports Interim Financial Results for the First Half of 2017 (Businesswire)
23.06.17		Publication of the Securities Note Having Obtained Visa No. 17-297 of the AMF in Connection with the Capital Increase of GenSight Biologics (Businesswire)
11.05.17		GenSight Biologics: Annual General Meeting on May 31, 2017 (Businesswire)
08.05.17		GenSight Biologics to Present Data on GS010 and GS030 at the Annual Meeting of ARVO (Businesswire)
03.05.17		Gensight Biologics Appoints Mohamed Genead as Chief Medical Officer (Businesswire)
26.04.17		GenSight Biologics Reports Its Cash Position as of March 31, 2017 (Businesswire)
19.04.17		GenSight Biologics to Attend Upcoming Investor Conferences (Businesswire)
13.03.17		GenSight Biologics Reports Full Year 2016 Financial Results (Businesswire)
20.12.16		GenSight Biologics Reports Sustained Visual Acuity Gain at 78 Weeks in Its Phase I/II Study with GS010 for the Treatment of Leber’s Hereditary Optic Neuropathy (LHON) (Businesswire)
09.11.16		GenSight Biologics to Present at the Stifel Healthcare Conference on November 15, 2016 in New York (Businesswire)

Zurück | 1 | 2 | Weiter

Newssuche

Meistgelesene Nachrichten

Pierer-Aktie letztlich zweistellig höher: KTM ist insolvent - Antrag auf Sanierung in Eigenverwaltung

voestalpine-Aktie zieht an: Erste Group stuft Aktie von "Accumulate" auf "Buy" hoch

Solana Kurs Prognose: 300 US-Dollar noch in diesem Jahr?

Pierer Mobility-Aktie unter Druck: KTM-Pleite - Schockstarre in der Region und bei den Zulieferern - Land OÖ signalisiert Bereitschaft Beschäftigten zu helfen

Rheinmetall-Aktie steigt: Rheinmetall will Munitionswerk in Litauen bauen

Immofinanz-Aktie springt hoch: Immofinanz schreibt schwarze Zahlen: Deutliche Ergebnisverbesserung

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2024 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	01.12.2024 04:53
Kaufwert:	EUR
	Hinzufügen Speichern